
    
      Open-label, single arm, non-controlled, dose ascending (50 mg/day, 100 mg/day and 200 mg/day)
      with three consecutive dose escalation periods.

      After signing an informed consent subject will enter a screening period and a run-in
      stabilization period. At the end of run-in period patients will enter treatment phase.
      MBX-8025 in ascending doses (50 mg, 100 mg, and 200 mg) will be given within three
      consecutive 4 weeks periods, for a total of 12 weeks. At the end of treatment, subjects will
      enter a follow-up period.
    
  